

Leukemia Hairy Cell

[View the current Leukemia Hairy Cell InDepth page on BioPortfolio.com \(PDF\)](#)
(http://www.bioportfolio.com/indepth/Leukemia_Hairy_Cell.html) - Regularly Updated.



Recent Publications on Leukemia Hairy Cell:

- [Hairy-cell leukemia with inaugural joint manifestations.](#)
*Hairy-cell leukemia is a chronic B-cell malignancy seen in adults. The...*3rd November, 2009
service de rhumatologie, CHD les Oudairies, 85000 La Roche Sur Yon,- Joint Bone Spine. 2009 Jul;76(4):416-20. Epub 2009 Jun 21. ([DOI Direct Link](#))
- [\[B-cell chronic lymphocytic leukaemia and the similar states\]](#)
*B-cell chronic lymphocytic leukaemia and the similar diseases are seen...*22nd October, 2009
Interni hematologicka klinika Lekarske fakulty MU a FN Brno,- Vnitr Lek. 2009 Sep;55(9):746-65.
- [Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.](#)
*Hairy cell leukaemia (HCL) was first described 50 years ago. Median...*11th September, 2009
The Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton,- Br J Haematol. 2009 Jun;145(6):733-40. Epub 2009 Mar 29. ([DOI Direct Link](#))
- [Risk factors for severe infection in patients with hairy cell leukemia: a long-term study of 73 patients.](#)
*Although the survival of patients with hairy cell leukemia (HCL) has been...*3rd September, 2009
Hematology, Amiens University Medical Center, Amiens, France.- Eur J Haematol. 2009 Sep;83(3):246-50. Epub 2009 Mar 19. ([DOI Direct Link](#))
- [CD200/OX2, a cell surface molecule with immuno-regulatory function, is consistently expressed on hairy cell leukaemia neoplastic cells.](#)
*Hairy cell leukaemia (HCL) was first described 50 years ago. Median...*4th August, 2009
- Br J Haematol. 2009 Jun;145(5):665-7. Epub 2009 Mar 12. ([DOI Direct Link](#))
- [Phase II trial of recombinant immunotoxin RFB4\(dsFv\)-PE38 \(BL22\) in patients with hairy cell leukemia.](#)
*PURPOSE: To conduct a phase II trial in chemoresistant hairy cell leukemia...*10th July, 2009
Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and- J Clin Oncol. 2009 Jun 20;27(18):2983-90. Epub 2009 May 4. ([DOI Direct Link](#))
- [Achievement of complete remission of refractory hairy cell leukemia by rituximab progressing after allogeneic hematopoietic stem cell transplantation.](#)
*Hairy cell leukaemia (HCL) was first described 50 years ago. Median...*27th June, 2009
- Int J Hematol. 2009 Apr;89(3):403-5. Epub 2009 Mar 31. ([DOI Direct Link](#))
- [\[Therapy in Hodgkin disease and non-Hodgkin lymphomas\]](#)
*The therapy of malignant lymphoproliferative diseases has changed many...*6th June, 2009
Simmelweis Egyetem, Altalanos Orvostudományi Kar, II. Belgyógyászati- Orv Hetil. 2009 Apr 5;150(14):651-5. ([DOI Direct Link](#))
- [Sweet syndrome as the presenting symptom of hairy cell leukemia.](#)

- Hairy cell leukaemia (HCL) was first described 50 years ago. Median...* 6th May, 2009
- Dermatol Online J. 2009 Feb 15;15(2):12.
- [Establishment of a hairy cell leukemia variant cell line, HCLv-07.](#)
Hairy cell leukaemia (HCL) was first described 50 years ago. Median... 6th May, 2009
Division of Hematology, Department of Internal Medicine, Juntendo- Acta Haematol. 2009;121(1):63-6.
Epub 2009 Apr 1. ([DOI Direct Link](#))
 - [Has success spoiled hairy cell leukemia research? Key questions go unanswered, despite big gains.](#)
CD103 is characteristically expressed in hairy cell leukemia (HCL), a... 30th April, 2009
- J Natl Cancer Inst. 2009 Mar 18;101(6):370-3. Epub 2009 Mar 10. ([DOI Direct Link](#))
 - [Immunophenotypic analysis of CD103+ B-lymphoproliferative disorders: hairy cell leukemia and its mimics.](#)
CD103 is characteristically expressed in hairy cell leukemia (HCL), a... 29th April, 2009
Genzyme Genetics, 521 W 57th St, New York, NY 10019, USA.- Am J Clin Pathol. 2009
Apr;131(4):586-95. ([DOI Direct Link](#))
 - [Visual disturbance as initial presentation of hairy cell leukemia.](#)
PURPOSE: Hairy cell leukemia (HCL) is a rare disorder that occasionally... 28th April, 2009
Department of Ophthalmology, Stanford University School of Medicine,- Eur J Ophthalmol. 2009
Mar-Apr;19(2):318-20.
 - [\[Hairy cell leukemia in young patients\]](#)
AIM: To characterize clinical symptoms, course, immediate and long-term... 7th April, 2009
- Ter Arkh. 2008;80(12):53-8.
 - [\[50-year-old man with weight loss and splenomegaly\]](#)
AIM: To characterize clinical symptoms, course, immediate and long-term... 17th February, 2009
Abteilung fur Hamatologie/intern, Onkologie St. Bernhard Hospital,- Dtsch Med Wochenschr. 2009
Feb;134(6):251-2. Epub 2009 Jan 29. ([DOI Direct Link](#))

Leukemia Hairy Cell Clinical Trials:



- [Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia](#)

Leukemia Hairy Cell Patents:



- 7435750- [Method of using substituted 3-aryl-5-aryl-\[1,2,4\]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7479483- [Tumor-targeted drug delivery systems and uses thereof](#)
- 7485657- [Anti-cytokine heterocyclic compounds](#)
- 7507762- [Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis](#)

[and the use thereof](#)

- 7511042- [Triazole compounds](#)
- 7514458- [Anti-cytokine heterocyclic compounds](#)
- 7517949- [Livin-derived peptides, compositions and uses thereof](#)
- 7521044- [Human histone deacetylase, HDAC9c](#)
- 7521071- [Formulation of oral compositions comprising arsenic trioxide and methods of use thereof](#)
- 7521446- [Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith](#)
- 7521542- [Humanized Fc.gamma.RIIB-specific antibodies and methods of use thereof](#)
- 7476741- [Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7470723- [Diphenylethylene compounds and uses thereof](#)
- 7470692- [Cytokine inhibitors](#)
- 7435755- [CDDO-compounds and combination therapies thereof](#)
- 7438910- [Therapeutic human anti-IL1-R1 monoclonal antibody](#)
- 7449477- [7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt \(protein kinase B\)](#)
- 7449570- [Use of nucleoside compounds for nonsense suppression and the treatment of genetic diseases](#)
- 7452901- [Anti-cancer phosphonate analogs](#)
- 7456260- [Humanized antibody](#)
- 7462461- [Compositions for inhibiting Sema7A and VLA-1 interaction and the methods of using the same](#)
- 7462694- [C-terminally truncated non-cytotoxic PAP mutants](#)
- 7468355- [Methods for inhibiting cancer and scar formation](#)
- 7468446- [Substituted heterocyclic compounds and uses thereof](#)
- 7528164- [Substituted 4-aryl-4h-pyrrolo\[2,3-h\]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof](#)
- 7528255- [Hydroxy, .omega.-carboxyaryl substituted diphenyl ureas and dirivatives thereof as raf kinase inhibitors](#)
- 7589092- [Prodrugs of heteroaryl compounds](#)
- 7592143- [Methods of treating diseases responsive to induction of apoptosis and screening assays](#)
- 7592332- [Cytokine inhibitors](#)
- 7592342- [Quinoxaline derivatives as PI3 kinase inhibitors](#)
- 7592422- [Modified plasminogen activator inhibitor type-1 and methods based thereon](#)
- 7595401- [Therapeutic compounds and their use in cancer](#)
- 7597884- [Hyperglycosylated polypeptide variants and methods of use](#)
- 7598353- [Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof](#)
- 7601700- [Modulation of eIF4E expression](#)
- 7604799- [EphA4 Antibodies](#)
- 7585888- [Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders](#)
- 7585837- [Reversible pegylated drugs](#)
- 7585647- [Nucleic acid encoding recombinant interferon](#)
- 7531560- [Anti-cytokine heterocyclic compounds](#)
- 7538252- [Drug design for tubulin inhibitors, compositions, and methods of treatment thereof](#)
- 7541344- [Modulation of survivin expression](#)
- 7557129- [Cyanopyridine derivatives useful in the treatment of cancer and other disorders](#)
- 7557251- [Production of gossypol co-crystals](#)
- 7560462- [Compounds useful for inhibiting CHK1](#)
- 7563791- [Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis](#)
- 7569568- [Cytokine inhibitors](#)
- 7576175- [Alpha-4 beta-1 integrin ligands for imaging and therapy](#)

- 7582645- [Pyrimidine derivatives for treatment of hyperproliferative disorders](#)
- 7608618- [Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1](#)

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

